Intellectual property from UCSD, WSU, UCF, Michigan Tech, N2 Biomedical, and Nanovation Partners represents the most comprehensive portfolio available to license with respect to implant nanotube surface treatment
Orlando, FL – October 17, 2016 – Nanovation Partners, LLC (www.nanovationpartners.com) and Michigan Technological University today announced a partnership agreement for commercialization of processes to nano-texturize medical implants. These advanced processes can simultaneously increase bone ingrowth and provide an antimicrobial barrier. The collaboration agreement extends Nanovation Partner’s leadership in commercialization of nano-texturing technology.
Craig Friedrich, PhD, Director of Michigan Tech’s Multi-scale Technologies Institute, commented, “What we're developing is a surface treatment that's more straightforward and economical than other processes. It speeds healing and is applicable to a broad range of implants. With this process, in conjunction with the technologies developed at other leading nano-technology universities and companies already in partnership with Nanovation Partners, we can fight infection and reduce inflammation. Our partnership with Nanovation Partners will speed and broaden the transfer of this technology to provide a clinical benefit for a broad range of patients.”
With this latest collaboration, Nanovation Partners has aligned with another well-published, recognized leader in the development of titanium dioxide (TiO2) nanotubes for modifying the surfaces of medical implants. It builds on Nanovation Partners’ growing list of partnerships with academic researchers at the University of California San Diego (UCSD), Washington State University (WSU), and University of Central Florida (UCF), and further broadens the company’s portfolio of five Issued and over 20 pending U.S. and international patents for nanotexturing processes and structures.
Researchers at Michigan Technological University and Washington State University have been issued separate U.S. patents for nanotexturing processes and structures that improve bone growth and provide anti-microbial properties, addressing both initial and long-term infections following implantation. The agreements with these institutions give Nanovation Partners, in part, exclusive rights to license the technologies to medical device companies in all medical areas.
“The partnership with Michigan Tech builds on Nanovation Partners’ strategic collaborations with leaders in nanotexturing technology,” said Dan Justin, President and CEO of Nanovation Partners. “We are first licensing technologies focused on nanotexturing existing implant surfaces, then, when applicable, licensing nanotechnologies that further enhance the textured surface. Our licenses with the four universities extend into all areas of medicine including orthopedics, cardiovascular, and neurovascular. Having demonstrated superior properties to other nanotextured and traditional implant surfaces in numerous in vivo and in vitro studies, our nanotube structure addresses all three major deficiencies of traditional implant material surfaces, by increasing hydrophilicity, enhancing osseointegration and by providing a surface that is unfriendly to pathogenic microbes. The agreement with Michigan Tech extends Nanovation Partners lead in developing nanotexturing technology for clinical use.”
Mr. Justin continued, “In addition to the first generation of nanotechnologies that enhance implants by nanotexturing their surfaces, the next generation of licensed technologies from our four research institution partners can be used as drug and antimicrobial delivery systems. For example, Michigan Tech’s technology has demonstrated extended release of the anti-inflammatory drug sodium naproxen after implant surgery in a study published in the journal RSC Advances. The technology may also be used on a variety of implants to reduce inflammation and promote healing. All of these technologies are now available for further development and licensing, and Nanovation Partners is actively seeking medical device partners who are interested in bringing this innovative approach to patients.”
Nanovation Partners has also recently partnered with N2 Biomedical of Bedford, Massachusetts (www.n2bio.com), a leading ISO-13485 certified surface treatment provider, who can perform the nanotexturing process on a service basis for interested device manufacturers.
Discover Nanotechnology at NASS (Booth #1837) in Boston, MA where Nanovation Partners will be exhibiting, October 26th through October 29th.
Michigan Technological University (www.mtu.edu) is a leading public research university developing new technologies and preparing students to create the future for a prosperous and sustainable world. Michigan Tech offers more than 120 undergraduate and graduate degree programs in engineering; forest resources; computing; technology; business; economics; natural, physical and environmental sciences; arts; humanities; and social sciences.
Nanovation Partners LLC (www.nanovationpartners.com) sponsored early research at the University of California at San Diego (UCSD) in the lab of Sungho Jin, PhD. This research showed enhanced osseointegration and reduced implant surface infection by forming tiny rows of metal oxide nanotubes on the implant surfaces. A comprehensive patent portfolio has since begun issuing with claims that cover a wide range of processes and structures. Nanovation Partners has also licensed Intellectual Property from Washington State University (WSU) related to antimicrobials with silver nano-particles on nanotubes and other nanostructures, the University of Central Florida (UCF) and Michigan Technological University related to nanotube processing.